Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9002860 | 0.85 | SLC1A2 (0.54) | SMN1; SMN2LMNAPOLBALDH1A1 | |
| SCHEMBL25678256 | 0.82 | MAPT (0.40) | KMT2AMEN1LMNAPOLB | |
| SCHEMBL20630873 | 0.80 | MEN1 (0.50) | KMT2AMEN1CYP2C19CYP1A2 | |
| SCHEMBL12140988 | 0.80 | HTR2C (0.48) | KMT2ASMN1; SMN2CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL15896085 | 0.78 | KMT2A (0.44) | KMT2AMEN1SMN1; SMN2CYP2C19NPC1 | |
| SCHEMBL4399509 | 0.77 | NPC1 (0.54) | SMN1; SMN2LMNANPC1POLBALDH1A1 | |
| SCHEMBL12995673 | 0.77 | NAMPT (0.57) | — | |
| SCHEMBL10117993 | 0.76 | TSHR (0.61) | KMT2ATP53MEN1SMN1; SMN2LMNA | |
| SCHEMBL9003061 | 0.75 | RECQL (0.54) | KMT2ACYP3A4CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL130859 | 0.75 | NAMPT (0.47) | KMT2AMEN1SMN1; SMN2CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139456-B2 | Chelating compounds and immobilized tethered chelators | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2015-09-22 | — | — | US | disclosed |
| US-20120061325-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2012-03-15 | — | — | US | disclosed |
| US-8066883-B2 | Removing aluminum from solution using chelating compounds and immobilized tethered chelators | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20110168636-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2011-07-14 | — | — | US | disclosed |
| US-7932326-B2 | Chelating compounds and immobilized tethered chelators | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090261043-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120061325-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | BTD, TTPA, SLC39A7 | KMT2A 409/4885TP53 3503/4885MEN1 2073/4885 |
| US-20090261043-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | BTD, SLC30A7, SLC39A7 | KMT2A 535/4885TP53 2963/4885MEN1 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.